Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL ...

Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL ... population of patients with hematologic malignancies (n=593) were decreased neutrophil count (46%), ...

Certain myeloid neoplasms, such as chronic neutrophilic leukemia (CNL) and chronic eosinophilic leukemia (CEL), lack the BCR::ABL1 fusion gene but exhibit distinct genetic markers like CSF3R ...

Patients diagnosed with chronic myeloid leukemia, chronic eosinophilic leukemia, or chronic neutrophilic leukemia were excluded. The researchers defined basophilia as a relative or absolute increase ...

Chronic lymphocytic leukemia (CLL) is a mature B-cell hematologic malignancy ... may result in low erythrocyte, platelet, and neutrophil counts. 2 Direct antiglobulin (Coombs) testing is recommended ...

Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm characterized by CSF3R mutations. Here, we report the first case of a CNL patient positive for a de-novo germline CSF3R T618I ...

Chronic neutrophilic leukemia is a rare blood cancer characterized by the overproduction of mature neutrophils, a type of white blood cell. Currently, no standard treatment exists, but emerging ...

The FDA has granted accelerated approval to asciminib as a first-line treatment for adults newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia, a rare type of blood cancer.